Empagliflozin (Jardiance) During Acute STEMI
Empagliflozin should generally be continued during acute STEMI in patients already taking it, but should not be newly initiated during the acute event itself. For patients presenting with STEMI who are already on empagliflozin, continuation is reasonable with careful monitoring for volume depletion and hemodynamic stability, while new initiation should be deferred until after the acute phase and revascularization are complete 1.
Key Considerations During Acute STEMI
Volume Status and Hemodynamic Monitoring
Assess volume status immediately upon presentation, as empagliflozin can cause intravascular volume depletion that may manifest as symptomatic hypotension or acute changes in creatinine 1.
Patients at highest risk for volume depletion include those with impaired renal function (eGFR <60 mL/min/1.73 m²), elderly patients, or those on loop diuretics—all common in STEMI presentations 1.
If volume depletion is present, correct this condition before continuing empagliflozin, as hemodynamic instability during acute MI can be exacerbated by SGLT2 inhibitor-induced diuresis 1.
Renal Function Considerations
Monitor renal function closely during the acute phase, as post-marketing reports document acute kidney injury requiring hospitalization and dialysis in patients receiving SGLT2 inhibitors 1.
Empagliflozin is contraindicated in patients on dialysis and should be used cautiously in those with acute kidney injury during STEMI 1.
Recent data shows empagliflozin preserves kidney function long-term after MI, but acute hemodynamic changes during STEMI require vigilant monitoring 2.
Timing of Initiation After STEMI
Evidence for Early Initiation
The EMPACT-MI trial (the largest and most recent high-quality study with 6,522 patients) initiated empagliflozin within 14 days after acute MI and found no significant reduction in the primary composite endpoint of heart failure hospitalization or death (HR 0.90,95% CI 0.76-1.06, p=0.21), though heart failure hospitalization alone was reduced (HR 0.77,95% CI 0.60-0.98) 3.
The EMMY trial initiated empagliflozin within 72 hours of PCI in 476 patients and demonstrated significant NT-proBNP reduction (15% lower, p=0.026) and improved left ventricular ejection fraction (1.5% absolute improvement, p=0.029) at 26 weeks 4.
A 2025 meta-analysis of 9 RCTs with 7,237 patients showed empagliflozin significantly reduced heart failure hospitalization (RR 0.70,95% CI 0.57-0.85) and improved ejection fraction, body weight, and systolic blood pressure without increasing adverse events 5.
Practical Initiation Strategy
Defer new initiation until after the acute phase (at least 24-72 hours post-PCI) when:
- Hemodynamic stability is confirmed 1
- Volume status is optimized 1
- Renal function is stable 1
- The patient is tolerating oral medications 1
Consider initiation before hospital discharge in patients with:
- Reduced LVEF (<45%) 3, 4
- Elevated NT-proBNP suggesting heart failure risk 4
- Diabetes mellitus or established cardiovascular disease 1
- Stable hemodynamics and adequate renal function (eGFR ≥30 mL/min/1.73 m²) 1
Safety Monitoring During Acute Phase
Critical Adverse Events to Monitor
Ketoacidosis risk: Assess for signs of metabolic acidosis regardless of blood glucose level, as SGLT2 inhibitors can cause euglycemic diabetic ketoacidosis 1.
Urinary tract infections: SGLT2 inhibitors increase UTI risk, including serious infections like urosepsis and pyelonephritis requiring hospitalization 1.
Fournier's gangrene: Though rare, this life-threatening necrotizing fasciitis of the perineum requires immediate recognition and empagliflozin discontinuation if suspected 1.
Hypoglycemia: If the patient is on insulin or insulin secretagogues during acute MI management, consider dose reduction to prevent hypoglycemia when empagliflozin is present 1.
Clinical Situations Requiring Temporary Discontinuation
Hold empagliflozin temporarily in patients with:
- Hemodynamic instability or cardiogenic shock 1
- Acute kidney injury or rapidly declining renal function 1
- Severe volume depletion 1
- Signs of ketoacidosis or metabolic acidosis 1
- Need for urgent surgical intervention (e.g., emergency CABG) 1
Long-Term Benefits Post-STEMI
Cardiac remodeling: Multiple studies show empagliflozin reduces left ventricular volumes, improves ejection fraction, and decreases NT-proBNP levels when initiated after MI 6, 7, 4, 5.
Heart failure prevention: The most consistent benefit across trials is reduction in heart failure hospitalization, even when overall mortality is not significantly affected 3, 5.
Kidney protection: Empagliflozin preserves estimated glomerular filtration rate over 24 months post-MI compared to placebo 2.
Microvascular protection: Preclinical and clinical data suggest empagliflozin reduces no-reflow phenomenon and microvascular injury, potentially through endothelial protection 7.
Common Pitfalls to Avoid
Do not initiate during active hemodynamic instability or before volume status is assessed and optimized 1.
Do not overlook renal function monitoring, especially in elderly patients or those receiving contrast during PCI 1.
Do not assume all SGLT2 inhibitors have identical evidence—the data presented here is specific to empagliflozin 3, 4, 5.
Do not forget to educate patients about signs of volume depletion, UTI symptoms, and genital mycotic infections before discharge 1.